Oragenics, Inc. (OGEN) |
|
2.8399 0.04 (1.43%)
|
09-26 14:48 |
|
Open: |
2.94 |
Pre. Close: |
2.8 |
|
High:
|
2.8399 |
Low:
|
2.8 |
|
Volume:
|
296 |
Market Cap:
|
7(M) |
|
|
|
Technical analysis |
as of: 2023-09-27 11:18:57 AM |
|
Short-term rate:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
|
Mid-term rate:
|
  |
| Target: |
Six months: 3.8 One year: 4.25 |
| Support: |
Support1: 2.65 Support2: 2.2 |
| Resistance: |
Resistance1: 3.26 Resistance2: 3.64 |
| Pivot: |
3.07  |
| Moving Average: |
MA(5): 2.91 MA(20): 3.11
MA(100): 3.23 MA(250): 6.09 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 10.4 %D(3): 16.2 |
| RSI: |
RSI(14): 40.6 |
| 52-week: |
High: 17.39 Low: 2.59 |
| Average Vol(K): |
3-Month: 11 (K) 10-Days: 5 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ OGEN ] has closed above bottom band by 13.4%. Bollinger Bands are 12% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
3.18 - 3.2 |
3.2 - 3.22 |
|
Low:
|
2.76 - 2.78 |
2.78 - 2.8 |
|
Close:
|
2.77 - 2.8 |
2.8 - 2.83 |
|
Company Description |
|
Oragenics, Inc. develops antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus; and Terra CoV-2, an intramuscular vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement with Precigen, Inc. and ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida. |
Headline News |
Mon, 07 Aug 2023
Oragenics, Inc. Announces Private Placement - Yahoo Finance
Mon, 05 Jun 2023
Oragenics Project to Develop a Variant-Agnostic Protein Antigen for ... - Business Wire
Mon, 26 Dec 2022
Trading Penny Stocks Under $1: Strategies for Success & 10 To Watch - Penny Stocks
Fri, 23 Dec 2022
Oragenics, Inc. Discloses One-for-Sixty Reverse Stock Split - Business Wire
Fri, 24 Jun 2022
Tampa biotech firm elevates board member to president, CEO - Business Observer
Tue, 04 Jan 2022
Should You Buy Oragenics Inc (OGEN) Stock After it Has Gained 15.56% in a Week? - InvestorsObserver
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: AMEX |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
0 (M) |
|
% Held by Insiders
|
0 (%) |
|
% Held by Institutions
|
0 (%) |
|
Shares Short
|
0 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
0 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
0 |
|
Return on Equity (ttm)
|
0 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
0 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
0 (M) |
Stock Valuations |
|
PE Ratio
|
0 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
0 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
